A clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulatory cell death for immune-mediated diseases. The company is advancing a multi-asset pipeline including AC-101, a RIPK2 inhibitor in development for ulcerative colitis, aiming to deliver targeted therapies for inflammatory and autoimmune conditions.